Media Coverage

How a Beleaguered Industry Needs to Adapt – and Why it Doesn’t Have a Choice

October 7, 2016

By Peter Miller, CEO of OptiNose   The pharmaceutical industry has had a rough go of it lately.  Between negative headlines (with the recent Mylan EpiPen controversy only the latest controversy), congressional inquiries and calls from insurers and the medical community to defend the price of medications, today’s value-focused healthcare landscape presents an unprecedented set…

Read More

OptiNose Plans Second New Drug

October 12, 2015

Philadelphia Business Journal  l   October 9, 2015 John George   A Bucks County company that has developed a “bi-directional, breath-powered” drug-delivery system, is getting ready to file its second new drug application.   OptiNose of Yardley announced positive results from late-stage testing of OPN-375, an experimental treatment for nasal polyposis. It expects to seek Food and Drug…

Read More

Peter Miller of OptiNose: To Work Here, Win the ‘Nice’ Vote

July 18, 2015

THE NEW YORK TIMES Corner Office By ADAM BRYANT   “I believe in culture so strongly and that one bad apple can spoil the bunch,” said Peter Miller.   Were you in leadership roles or entrepreneurial when you were younger? I did have a real passion and an interest in business for some reason. Part…

Read More

FORTUNE: Is the future of pharma about making good drugs great

Fortune | February 27, 2015

Is the future of pharma about making good drugs great? by Laura Lorenzetti   Some companies are asking how existing therapies — medicines that are known, tested and approved — can be even more effective. The cost of developing new drugs continues to soar. These days, drug developers can expect to shell out more than…

Link to Article

Avanir, OptiNose Enter Exclusive North America License Deal

The Wall Street Journal | July 2, 2013

Avanir Pharmaceuticals Inc. (AVNR) and OptiNose AS reached an exclusive North American licensing deal to develop OptiNose’s Breath Powered system, a potential treatment for acute migraines.

The companies claim that, if approved, the product would be the first and only fast-acting, dry-powder nasal delivery of migraine headache drug sumatriptan.

Link to Article

A breath of fresh money for migraine treatment

Philadelphia Business Journal | July 1, 2013

OptiNose signed a licensing deal worth up to $110 million for its experimental migraine headache treatment. OptiNose signed a licensing deal worth up to $110 million for its experimental migraine headache treatment. The treatment, in late-stage testing, uses the Bucks County medical device company’s Breath Powered intranasal drug-delivery system.

Read More

Peter Miller, CEO of OptiNose, talks with The New York Times about his entrepreneur spirit

The New York Times | November 19, 2011

I GREW up in East Falls, a neighborhood of northwest Philadelphia. My father spent his career as a radiologist, working and teaching at the Hospital of the University of Pennsylvania. My mother, who was a nurse, stayed at home to raise my three siblings and me.

Link to Article

OptiNose is Breathing Some New Life into Old Drugs

Philadelphia Business Journal | June 3, 2011

Peter Miller was sniffing around for his next entrepreneurial opportunity last summer when he decided to join OptiNose as CEO of the Bucks County company that has developed a new way to deliver medicine.

Download (353KB PDF)

Radius, 3M Drug Delivery partner on osteoporosis drug; OptiNose wins award for nasal delivery

Fierce Drug Delivery | May 25, 2011

Radius Health and 3M Drug Delivery Systems are getting together to develop a transdermal version of BA058, which is Radius’ parathyroid hormone-related protein analog to treat osteoporosis.

Link to Article

Nose Spray that Eases A Migraine in Minutes

Mail Online | December 21, 2010

A pipe-like puffer device that blows powdered medicine up the nose could banish the pain of migraine in less than two hours.

Link to Article

OptiNose Aims High with Nasal Drug Delivery Device

Fierce Medical Devices | September 29, 2010

Yardley-PA based OptiNose is hoping to use its nasal-spray device to revolutionize the way existing drugs are delivered, boosting efficacy, lowering dosages and potentially replacing vaccines all together.

Link to Article

Yardley Start-Up Hoping Medical Device Delivers

The Philadelphia Inquirer | September 27, 2010

Peter Miller and Ramy A. Mahmoud have a shared definition of brilliant: an idea so “blindly simple” that, as Mahmoud puts it, one wonders why no one had thought of it before.

Download (908KB PDF)

OptiNose Reveals Bi-directional Nasal Device Phase II Results

August 11, 2010

OptiNose, a provider of bi-directional nasal activity technology, has released positive Phase II trial results evaluating the bi-directional nasal device delivering fluticasone, a nasal steroid, which demonstrated to be effective in progressively reducing the size or eliminating nasal polyps in patients with chronic rhinosinustis (CRS) with nasal polyps.

Read More

OptiNose Lands $48.5 Million in Funding, New CEO

The Philadelphia Inquirer | June 10, 2010

One of the local founders of Take Care Health Systems has jumped into the top job of another health-care company that’s moving here.

Link to Article

Breath-Actuated Bi-Directional Delivery Sets the Nasal Market on a New Course

ONdrugDelivery | October 10, 2005

Nasal drug delivery is already a thriving market but there is still a wide gap between what has been achieved in the past and what could be achieved were the full potential of this highly attractive administration route released. This article describes a technological breakthrough by OptiNose that has allowed the company to make that hitherto elusive step of achieving truly optimal nasal drug delivery.

Download (985KB PDF)